Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06628778 · ClinicalTrials.gov registry record · Phase 3
Collaborative Risk-stratified Investigation in Thrombosis-prone Inpatients With Critical Illness: Anticoagulation With LMWH in Teens for ThromboProphylaxis (CRITICAL-Teens-TP).
A Phase 3 study, sponsored by Johns Hopkins All Children's Hospital.
- Not yet
- Registry status
- Phase 3
- Development phase
- 802
- Enrollment target
NCT06628778 is a Phase 3 study that has not yet begun recruiting, run by Johns Hopkins All Children's Hospital. The registered enrollment target is 802 participants.
The verdict
NCT06628778, a Phase 3 study, has not yet begun recruiting, sponsored by Johns Hopkins All Children's Hospital.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 802 participants
- Enrollment target
Study Summary
Critically ill adolescents are at greatest risk for developing hospital-acquired venous thromboembolism. To date, no phase 3 randomized controlled trials have been conducted for pharmacological thromboprophylaxis as primary venous thromboembolism prevention in children. The investigators will perform a United States definitive multicenter phase 3 randomized controlled trial of the low molecular weight heparin enoxaparin as primary venous thromboembolism prophylaxis among critically ill adolescents who are classified a priori as high risk based upon the investigators validated risk prediction models.
Interventions
- DRUG Enoxaparin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 802 participants |
| Start Date | 2027-04-15 |
| Est. Completion | 2035-04-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06628778
The ClinicalTrials.gov registry entry for NCT06628778 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 802 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins All Children's Hospital, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Enoxaparin is the first listed.
NCT06628778 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06628778 about?
NCT06628778 is a clinical study titled "Collaborative Risk-stratified Investigation in Thrombosis-prone Inpatients With Critical Illness: Anticoagulation With LMWH in Teens for ThromboProphylaxis (CRITICAL-Teens-TP).". Critically ill adolescents are at greatest risk for developing hospital-acquired venous thromboembolism. To date, no phase 3 randomized controlled trials have been conducted for pharmacological thromboprophylaxis as primary venous thromboembolism prevention in children. The investigators will perfor...
What is the current status of trial NCT06628778?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 802 participants. The study started on 2027-04-15. Estimated completion is 2035-04-15.
What interventions are being tested in trial NCT06628778?
The interventions under investigation include: Enoxaparin (DRUG).
Who is sponsoring clinical trial NCT06628778?
This trial is sponsored by Johns Hopkins All Children's Hospital, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.